Nerve stimulators for migraine: the FDA-cleared devices that actually have trials behind them

What these devices actually are (and are not)

Start by drawing the boundary, because it is the whole story. There is a sprawling consumer market of “nerve reset,” “vagal tone,” and “calm” gadgets that clip on your ear or buzz your wrist and promise to fix your nervous system. Most of that market is mechanism-in-search-of-a-result, and we have taken it apart elsewhere. This article is deliberately not about that category. It is about three specific devices that cleared a much higher bar: they are regulated medical devices, cleared by the FDA for migraine or headache, and each one was tested against a sham device in a randomized controlled trial. That distinction — trial-backed medical device versus wellness gadget — is the reason this piece grades most claims MODERATE rather than the HYPE that generic nerve-stim marketing earns.

The three devices, plainly:

• Cefaly — an external trigeminal nerve stimulation (e-TNS) device. A small unit adheres to the centre of the forehead and delivers electrical pulses to the supraorbital and supratrochlear branches of the trigeminal nerve. It is FDA-cleared for both acute treatment of a migraine attack and preventive use, and is available over the counter in the United States.¹
• gammaCore — a non-invasive vagus nerve stimulation (nVNS) device. A handheld unit is pressed against the side of the neck over the vagus nerve for a couple of minutes. It is FDA-cleared for migraine and, notably, for episodic cluster headache — a brutal, distinct headache disorder where the evidence for nVNS is actually among its strongest.³⁴
• Nerivio — a remote electrical neuromodulation (REN) armband, controlled by a smartphone app, worn on the upper arm during an attack. Rather than stimulating a head nerve directly, it stimulates arm nerves to recruit a brain-based pain-dampening circuit. It is FDA-cleared for acute and preventive treatment of migraine.⁵⁶

Migraine itself is not a bad headache; it is a neurological disorder involving trigeminal and central pain pathways, often with nausea, light and sound sensitivity, and sometimes aura. It has no cure. That is precisely why a drug-free option with a plausible nerve target and real randomized data is worth taking seriously — and worth grading with discipline rather than enthusiasm.

The mechanism: three nerves, three routes to the same pain

Each device modulates a pain-relevant nerve pathway, but by a different route. Understanding the three routes is what separates “a jolt that feels like something” from a targeted intervention.

Cefaly targets the trigeminal system directly. The trigeminal nerve is the central player in migraine — the pathway that carries head pain and, when sensitized, sustains an attack. By delivering rhythmic electrical stimulation to its forehead branches, e-TNS is thought to dampen excitability in this pathway and reduce the pain signal it pulls. It is the most anatomically on-the-nose approach: stimulate the nerve most implicated in migraine, where you can reach it under the skin of the forehead.¹

gammaCore works through the vagus nerve. The vagus is a long cranial nerve with wide reach, and stimulating it non-invasively at the neck appears to modulate central pain-processing hubs — including brainstem regions that gate trigeminal pain — and to influence the release of pain-related neurotransmitters. This is a genuinely different mechanism from the “vagal tone for calm” story sold by consumer gadgets; here the target is the headache circuitry, and the clearance and trials are headache-specific.³

Nerivio uses conditioned pain modulation. This is the cleverest and least obvious route. The armband stimulates sensory nerves in the upper arm, and that remote input activates a built-in descending pain-control system in the brainstem — conditioned pain modulation, sometimes described as “pain inhibits pain.” A non-painful stimulus in one part of the body recruits a circuit that turns down pain reporting elsewhere, including in the head. The device is not touching the head at all; it is borrowing the body’s own analgesic wiring.⁵

None of these mechanisms is speculative hand-waving; each is grounded in established headache neurobiology. But mechanism is not proof of benefit — plenty of plausible mechanisms fail in trials. The reason these three earn attention is that they were then actually tested against sham.

The wellness market sells a jolt and a promise. These three devices sell a specific nerve target and a sham-controlled trial. That is the entire difference — and it is the difference between HYPE and MODERATE.

The evidence: sham-controlled trials, device by device

The right way to read this category is one device at a time, because they were cleared on separate evidence and the strength varies.

Cefaly (e-TNS). For acute treatment, the ACME trial (Chou 2019) randomized migraine patients to a one-hour session of e-TNS or a sham device during an attack. Active stimulation significantly outperformed sham on pain reduction at one hour and on pain freedom, with the benefit holding at two hours.¹ For prevention, the earlier PREMICE trial (Schoenen 2013) randomized patients to daily 20-minute supraorbital stimulation or sham over three months; the active group had significantly fewer migraine days and a higher responder rate, though it did not separate from sham on every secondary measure.² Two trials, two indications, both positive on their primary signal — but both modest in magnitude. That is a MODERATE, not a slam dunk.

gammaCore (nVNS). The acute migraine anchor is the PRESTO trial (Tassorelli 2018), which found nVNS superior to sham for pain freedom at 30 and 60 minutes after an attack.³ The more striking evidence is in cluster headache: the ACT1 trial (Silberstein 2016) showed nVNS provided significant, rapid, sustained benefit for episodic cluster headache — a disorder notoriously hard to abort — while not separating from sham for chronic cluster.⁴ The honest reading is that nVNS is a modest add-on for migraine and a genuinely useful option for episodic cluster, which is a meaningful niche given how few good acute cluster treatments exist. MODERATE overall, with the cluster indication being the more robust part of the story.

Nerivio (REN). The pivotal acute trial (Yarnitsky 2019) was a double-blind, sham-controlled, multicentre study in which active REN clearly beat sham for two-hour pain relief — roughly two-thirds of active users reached pain relief versus under 40% on sham — and also improved pain freedom.⁵ A later randomized, placebo-controlled trial (Tepper 2023) then showed that using REN every other day significantly reduced monthly migraine days versus placebo, extending the device from acute rescue into prevention.⁶ Two positive randomized trials across two indications is a solid base for a newer device — enough for MODERATE rather than merely EMERGING — while acknowledging the evidence is younger and heavily tied to the manufacturer.

Step back from the individual rows and the pattern is consistent: every device separated from sham on its primary acute endpoint, the effects are real but moderate, and the more recent devices lean on fewer, mostly manufacturer-run trials. A neuromodulation-for-migraine review by Puledda and Goadsby reaches a similar balanced conclusion — these are legitimate, evidence-supported options that expand the toolkit, particularly for people who cannot use drugs, without pretending to match the strongest pharmacological therapies.⁷ That is the fair frame: real medicine at a modest dose, not a miracle and not a gimmick.

Who the trials actually studied

Rather than tell you which device to buy — that is a clinician’s call, tied to your specific migraine pattern, other treatments, and insurance — it is more useful to describe who the trials enrolled and where the fit is cleanest. Rule things out first.

• Foundational (diagnosis and a plan first). Before any device, migraine needs to be a real, clinician-confirmed diagnosis, not a self-label, and red-flag features (thunderclap onset, new headache after 50, neurological changes, worst-ever headache) must be excluded by a doctor. The backbone of migraine care remains identifying triggers, acute and sometimes preventive medication, and lifestyle levers — sleep, hydration, stress. Devices sit on top of that, not instead of it.
• Evidence-supported (what the trials tested). The pivotal trials studied adults with episodic migraine using each device as directed: Cefaly for a 20-minute (preventive) or one-hour (acute) forehead session, gammaCore as brief neck stimulations per attack, and Nerivio as a 45-minute arm session at attack onset or every other day for prevention.¹⁵ If your situation matches the trial population — episodic migraine, wanting a drug-sparing option — the evidence above applies most directly.
• Clinician-guided (the higher-value cases). The strongest rationale for these devices is when drugs are a poor fit: people with medication-overuse headache trying to cut acute drug use, those who cannot tolerate triptans or preventives, and pregnancy, where drug options narrow sharply and a drug-free option is genuinely appealing. gammaCore for episodic cluster headache is its own high-value niche. All of these belong in a conversation with a neurologist, because the device choice and the surrounding plan matter more than the gadget itself.⁷

The through-line: the closer your use matches a trial population and a clinician-set plan, the more the evidence transfers. Buy a device off a headline and use it outside that frame, and you are extrapolating past the data.

Grey areas: modest effects, cost, and the cure myth

Three honest limitations keep this category from being a clear win, and they deserve stating as plainly as the positive trials.

The first is effect size and evidence quality. Beating sham is a real bar, and all three devices clear it — but the gap between active and sham is moderate, not dramatic, and a substantial share of the benefit in any device trial is the well-known placebo response that headache disorders show. Many of the trials, especially for the newer devices, are industry-sponsored and relatively small, which is not disqualifying but does warrant the conservative grade. This is why the acute-relief claims land at MODERATE: consistent, replicated, plausible — but not overwhelming.

The second is the practical friction: cost, insurance, adherence, and comfort. These devices are not cheap, coverage is inconsistent, and some people find the sensation on the forehead or neck unpleasant enough to stop, or simply do not keep up with a device the way the trials required. A treatment that works only when used consistently is only as good as real-world adherence, and that is a genuine gap between trial and kitchen table.

The third is the cure myth, and it is the one to be bluntest about. No nerve-stimulation device cures migraine, reverses the underlying disorder, or replaces medical care. It provides symptomatic help — sometimes rescuing an attack, sometimes trimming migraine days — while you use it, on top of a proper treatment plan. Any marketing that frames one of these as a standalone fix is overstating what even the best trial supports, which is exactly why that specific claim grades HYPE while the device-specific relief claims grade MODERATE.⁷

Open questions

The gaps here are specific and worth naming. First, head-to-head data are missing — no rigorous trial pits Cefaly against gammaCore against Nerivio, so “which device is best” has no evidence-based answer, only mechanism-based guesses. Second, who responds is unclear: the trials rarely identify which patients get meaningful benefit versus which get little, so device selection is still trial-and-error. Third, long-term and real-world durability is thin — most trials run weeks to a few months, and how well benefit and adherence hold over years of daily or per-attack use is not well characterized.⁶ Fourth, the independence of the evidence would improve with more non-manufacturer trials, particularly for the newer devices.⁵⁷ None of these gaps overturn the core finding that the devices beat sham; they define how confidently, and for whom.

The verdict

The FDA-cleared migraine neuromodulation devices — Cefaly, gammaCore, and Nerivio — are the rare corner of the nerve-stimulation market that survives contact with the evidence. Each targets a real, headache-relevant nerve pathway, each was tested against a sham in a randomized trial, and each separated from that sham on its primary acute endpoint, with two of the three carrying preventive data as well.¹³⁵ That earns a legitimate MODERATE grade — a long way above the HYPE that generic “nerve reset” gadgets deserve, and honestly short of the potency of the best migraine drugs. The single strongest thing about them is not their power; it is their safety: drug-free, low adverse-event, and therefore uniquely valuable for people who cannot or should not use migraine medication.

So who are they for? If you have a clinician-confirmed migraine diagnosis and you want a drug-sparing tool — because drugs fail you, because you are managing medication-overuse headache, because you are pregnant, or because you have episodic cluster headache and gammaCore is on the table — then these devices are among the more defensible non-drug options available, precisely because they carry real trials rather than testimonials. Just hold the expectation at the right level. They are adjuncts that can rescue some attacks and shave some migraine days while you use them, on top of a plan your neurologist sets. They are not cures, they are not replacements for medical care, and choosing the right one is a clinical decision, not a shopping one. Judged as what they actually are — evidence-supported, drug-free additions to migraine management — they belong in the conversation. That is a sentence very few consumer nerve-stimulation products can earn.

For the broader map of recovery and physiological devices, our reads on TENS units for musculoskeletal pain and HRV-training wearables sit next to this one — and if you want the calm-and-vagal-tone side of nerve stimulation, our vagus nerve stimulation read draws the line between medical devices and wellness gadgets. For the physical-recovery lane, see compression boots, percussion massage guns, and the calming-supplement counterpart, L-theanine.